Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits

European Journal of Pharmacology
M AlegretJ C Laguna

Abstract

The effect of atorvastatin (3 mg kg(-1) day(-1)), simvastatin (3 mg kg(-1) day(-1)) and bezafibrate (100 mg kg(-1) day(-1)) administered for 4 weeks to male New Zealand white rabbits on enzyme activities related to lipid metabolism has been studied. Only the statins reduced plasma cholesterol values, while none of the drugs modified plasma triglyceride or high density lipoprotein (HDL)-cholesterol concentrations, nor the activity of enzymes such as hepatic diacylglycerol acyltransferase, lipoprotein lipase or hepatic lipase, directly involved in triglyceride metabolism. Both statins elicited similar increases in the hepatic microsomal 3-hydroxy-3-methyl-glutaryl Coenzyme A (CoA) reductase activity (147 and 109% induction for simvastatin and atorvastatin, respectively), and none of the drugs assayed modified hepatic acyl-coenzyme A:cholesterol acyltransferase activity significantly. Only bezafibrate induced a significant 57% reduction in the activity of hepatic microsomal cholesterol 7alpha-hydroxylase. Regarding the rate limiting enzyme of phosphatidylcholine biosynthesis, CTP:phosphocholine cytidylyl transferase, atorvastatin and bezafibrate behaved similarly, decreasing the enzyme activity in the liver by 45% and 54%, respect...Continue Reading

References

Jan 1, 1992·Methods in Enzymology·P A Weinhold, D A Feldman
Mar 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Z R VlahcevicP B Hylemon
Nov 1, 1991·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M BertolottiN Carulli
Apr 15, 1991·Biochemical Pharmacology·A SatoT Kamei
Jan 1, 1991·Khirurgiia·O P KurguzovA S Tatevosian
Jan 1, 1991·European Journal of Clinical Pharmacology·Y ChaoA W Alberts
Jan 1, 1991·European Journal of Clinical Pharmacology·M J TikkanenE Helve
Jan 1, 1991·European Journal of Clinical Pharmacology·D StåhlbergB Angelin
Jan 1, 1991·European Journal of Clinical Pharmacology·E F StangeH Ditschuneit
Jan 1, 1991·European Journal of Clinical Pharmacology·L Kłosiewicz-Latoszek, W B Szostak
Jun 14, 1990·Biochimica Et Biophysica Acta·B V KhanM Heimberg
Jul 13, 1987·Biochimica Et Biophysica Acta·I Björkhem, L Berglund
Oct 1, 1985·Biochemical Society Transactions·B G Lake, T J Gray
Dec 29, 1974·Biochimica Et Biophysica Acta·D J ShapiroR T Schimke
Apr 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D StåhlbergB Angelin
Jun 1, 1995·The New England Journal of Medicine·R J Havel, E Rapaport
Nov 1, 1993·Metabolism: Clinical and Experimental·R B SimsoloP A Kern
Jan 1, 1994·The Medical Clinics of North America·M L Larsen, D R Illingworth
Feb 1, 1993·Prostaglandins, Leukotrienes, and Essential Fatty Acids·C Y HongM S Shiao
Aug 1, 1996·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·L A DostalJ A Anderson
Nov 1, 1996·Clinical Pharmacokinetics·J P Desager, Y Horsmans

❮ Previous
Next ❯

Citations

Sep 24, 2004·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Seon-Min JeonMyung-Sook Choi
Sep 12, 2001·Biochemical Pharmacology·N RoglansJ C Laguna
Nov 24, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·J KobayashiM Shinomiya
Sep 12, 2002·European Journal of Pharmacology·Gemma LlaveríasMarta Alegret
Feb 19, 2000·Current Opinion in Lipidology·J Davignon, R Laaksonen
Dec 2, 2004·The Tohoku Journal of Experimental Medicine·Marek VeckaAles Zák
Jul 11, 2006·The Spine Journal : Official Journal of the North American Spine Society·Albert Juang Ming YeeJung U Yoo
Nov 3, 2020·TheScientificWorldJournal·Hamad Abdulsalam Hamad AlfarisiChe Anuar Che Mohamad

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.